Article Versions Notes

Niederle MB, Binter T, Riss P, Niederle B, Scheuba C. The Value of Pretherapeutic Basal Calcitonin Cut-Offs for the Therapeutic Strategy and Prediction of Long-Term Outcome of Patients with Medullary Thyroid Cancer—A 30-Year Single-Center Experience. Cancers. 2024; 16(19):3343. https://doi.org/10.3390/cancers16193343

Niederle, Martin B., Teresa Binter, Philipp Riss, Bruno Niederle, and Christian Scheuba. 2024. "The Value of Pretherapeutic Basal Calcitonin Cut-Offs for the Therapeutic Strategy and Prediction of Long-Term Outcome of Patients with Medullary Thyroid Cancer—A 30-Year Single-Center Experience" Cancers 16, no. 19: 3343. https://doi.org/10.3390/cancers16193343

Niederle, M. B., Binter, T., Riss, P., Niederle, B., & Scheuba, C. (2024). The Value of Pretherapeutic Basal Calcitonin Cut-Offs for the Therapeutic Strategy and Prediction of Long-Term Outcome of Patients with Medullary Thyroid Cancer—A 30-Year Single-Center Experience. Cancers, 16(19), 3343. https://doi.org/10.3390/cancers16193343